Paediatric psychopharmacology has entered a new and exciting era, with a substantial increase in the number of randomised controlled trials in paediatric mood and anxiety disorders. Although not a child and adolescent psychiatrist, I
Why is this an issue now?
The idea of SSRI (selective serotonin reuptake inhibitor)-associated suicidality first came to light in the early 1990s, yet despite more than a decade of study this critical question has yet to be answered definitively. The issue appears to have erupted again on 10 June 2003 when the British Medicines and Healthcare Products Regulatory Agency (MHRA) issued a press release prohibiting the use of paroxetine in children and adolescents under the age of 18.
Their decision was based on a review of unpublished data submitted by GlaxoSmithKline. Upon analysis of data from three trials of paroxetine in paediatric depression, all of which were negative, it emerged that paroxetine was associated with a two-to threefold higher rate of self-harm and suicidal behaviour than placebo. The MHRA also reported that suicidality appeared to be a significant risk with all antidepressants that were assessed, other than fluoxetine.
In contrast to other SSRIs, data from three clinical trials submitted on the use of fluoxetine in paediatric depression indicated that there was no increased risk of suicide-related events or attempted suicide.
About a week later, the US Food and Drug Administration (FDA) issued a weaker warning noting the controversy and advising dose monitoring because of the possible increased risk of suicide. The FDA did, however, point out that of the more than 4 000 children and adolescents who had participated in these studies, none had actually committed suicide. Furthermore, it was clear from the data submitted that adverse events suggestive of suicidality (broadly taken to include ideation, self-harm, suicide attempts) had been captured and coded differently by different trial sponsors and that assessment of suicidality had been largely elicited through basic, unstructured inquiry or a single item on a depression rating scale.
Suicide warnings
A contentious and emotional public advisory committee meeting on the risk of treatment-emergent self-harming behaviours associated with SSRI use in children and adolescents followed, after which the FDA requested on 22 
Mechanisms of suicidality and SSRIs
There are three possible mechanisms by which these medications may potentially precipitate suicidality. First, behavioural activation/disinhibition induced by the SSRIs may make latent suicidal thoughts more explicit and patients may be inclined to act on them when activated/disinhibited.
Second, akathisia or intense restlessness, a rare side-effect associated with SSRIs, may be so disturbing for some patients that they may consider suicide rather than endure the uncontrollable restless feelings. Akathisia is a side-effect that patients can be warned about and that clinicians can look for closely and treat with adjunctive medication, if needed. The third mechanism may be the natural history of recovery from depression, which when treated effectively is usually associated with a resolution of physical symptoms (lack of energy, sleep and appetite disturbances) first, before any observable improvement in subjective depressed mood. As energy levels begin to recover in the first week or two of starting medication, the risk of suicide may increase in patients who previously lacked the energy or motivation to attempt it. statistically and clinically significant drug-placebo differences.
Benefits versus risks
For example, in two recent randomised controlled trials of sertraline in children and adolescents (aged 6 -17) with DSM-IV defined major depressive disorder, undertaken at the request of the FDA, 69% of those who were taking sertraline were classified as responders compared with 59% of patients taking placebo. 6 While these differences were statistically significant, the mean change in scores from baseline to endpoint on the primary outcome measure, the Children's Depression Rating Scale-Revised, between the groups was so small so as to be of minimal clinical significance. In addition to high placebo response rates, other problems include nonpublication of negative findings, withholding of unfavourable data and under-reporting of adverse events. 
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